We are live on ! Find out more
CBIO

Crescent Biopharma
CBIO

75 hedge funds and large institutions have $180M invested in Crescent Biopharma in 2019 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 19 increasing their positions, 19 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

185% more call options, than puts

Call options by funds: $94K | Put options by funds: $33K

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

0% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 19

0.08% less ownership

Funds ownership: 1.04% → 0.96% (-0.08%)

4% less funds holding

Funds holding: 78 → 75 (-3)

12% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 25

66% less capital invested

Capital invested by funds: $535M → $180M (-$356M)

Holders
75
Holders Change
-3
Holders Change %
-3.85%
% of All Funds
1.64%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
22
Increased
19
Reduced
19
Closed
25
Calls
$94K
Puts
$33K
Net Calls
+$61K
Net Calls Change
+$1.44M

Top Buyers

1
BI
BVF Inc
California
+$47.3M
2
CCM
Camber Capital Management
Massachusetts
+$22.5M
3
Millennium Management
Millennium Management
New York
+$1.27M
4
BCM
Bridgeway Capital Management
Texas
+$1.06M
5
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
+$859K

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$36.3M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$26.8M
3
Franklin Resources
Franklin Resources
California
-$20.5M
4
Jennison Associates
Jennison Associates
New York
-$16.9M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$13.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Franklin Resources
76
Franklin Resources
California
– -$20.5M -17,188 Closed
Jennison Associates
77
Jennison Associates
New York
– -$16.9M -14,167 Closed
Janus Henderson Group
78
Janus Henderson Group
United Kingdom
– -$13.1M -11,007 Closed
SAM
79
Sectoral Asset Management
Quebec, Canada
– -$6.59M -5,528 Closed
ACM
80
Asymmetry Capital Management
California
– -$5.94M -4,980 Closed
Man Group
81
Man Group
United Kingdom
– -$5.91M -4,955 Closed
Hudson Bay Capital Management
82
Hudson Bay Capital Management
Connecticut
– -$3.58M -3,000 Closed
Allianz Asset Management
83
Allianz Asset Management
Germany
– -$2.38M -1,999 Closed
USAA
84
United Services Automobile Association
Texas
– -$1.43M -1,200 Closed
TD Asset Management
85
TD Asset Management
Ontario, Canada
– -$765K -642 Closed
MCM
86
Moore Capital Management
New York
– -$596K -500 Closed
State of Wisconsin Investment Board
87
State of Wisconsin Investment Board
Wisconsin
– -$554K -465 Closed
ECM
88
Endurant Capital Management
California
– -$504K -423 Closed
Rafferty Asset Management
89
Rafferty Asset Management
New York
– -$412K -346 Closed
DekaBank Deutsche Girozentrale
90
DekaBank Deutsche Girozentrale
Germany
– -$251K -218 Closed
PCM
91
Prelude Capital Management
New York
– -$239K -201 Closed
MIM
92
MetLife Investment Management
New Jersey
– -$198K -166 Closed
GCP
93
GSA Capital Partners
United Kingdom
– -$185K -155 Closed
MLICM
94
Metropolitan Life Insurance Company (MetLife)
New York
– -$140K -117 Closed
CM
95
Caption Management
Oklahoma
– -$132K -110 Closed
AG
96
Aperio Group
California
– -$49K -41 Closed
Canada Life
97
Canada Life
Manitoba, Canada
– -$45K -38 Closed
Simplex Trading
98
Simplex Trading
Illinois
– -$14.8K -23 Closed
SFG
99
SevenBridge Financial Group
Pennsylvania
– -$6K -5 Closed
1 2 3
4

CBIO Hedge Fund Activity: Q3 2019 in Review

75 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q3 2019, worth a combined $180M — down 66% from $535M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of CBIO and 22 opened new positions — a net loss of 3 holders — while 19 trimmed existing stakes and 19 added.

The largest buyer was BVF Inc, opening a new position worth an estimated $47.3M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $36.3M sold.

  • 75 institutional investors held Crescent Biopharma (CBIO) as of Q3 2019, down from 78 in Q2 2019.
  • Funds reported $180M of Crescent Biopharma stock for Q3 2019, down 66% quarter-over-quarter.
  • 22 funds opened new Crescent Biopharma positions in Q3 2019 and 25 closed out, a net change of -3 holders.
  • The largest Crescent Biopharma buyer in Q3 2019 was BVF Inc, an estimated $47.3M added.
  • The largest Crescent Biopharma seller in Q3 2019 was T. Rowe Price Associates, an estimated $36.3M sold.

Based on aggregated 13F filings for Q3 2019.